tured diagnostic interviews. In post hoc analyses, individuals with schizophrenia had significantly shorter mean telomere lengths than controls (P = 0.002) (Figure 1a ; Supplementary Table S1A) .
In a second study, we analyzed a group in which age was matched and all individuals were of a single sex, male. Our rationale was that telomere attrition is not linear at all ages and can differ between the sexes. 5 Thus, we recruited 20 additional male individuals with schizophrenia and added them to cohort A (total n = 33). In addition, we recruited 12 unaffected males and added them to the existing male controls (total n = 26). Telomere lengths were measured and analyzed separately from the previous study. Again, we observed that individuals with schizophrenia had significantly shorter mean telomere lengths than unaffected controls (P = 0.008) (Figure 1b ; Supplementary Table S1B) .
Chronic antipsychotic treatment could affect telomere length. However, there was no correlation between current antipsychotic dose (r = À0.071, P = 0.66) and estimated lifetime antipsychotic dose (r = 0.045, P = 0.78) with telomere length (Supplementary Figure S1 ).
Telomere erosion appears to be occurring rapidly in individuals with schizophrenia. By their mid-to late 30's, the mean T/S (a measure of telomere length 4 ), of individuals with schizophrenia was lower than controls by about 0.37-0.41 (Figures 1a and b;  Supplementary Tables S1A and B) , which corresponds to approximately 1580-1750 bp telomeres (see Supplementary Methods). Since telomere lengths were measured after about 20 years of illness in schizophrenia (mean age 36.2-38.8 years), we estimate that the rate of telomere loss has more than doubled with the onset of schizophrenia, and that lymphocytes in individuals with schizophrenia had aged the equivalent of at least 25 years more than their control counterparts. It should be noted that these estimates are based on cross-sectional studies, and longitudinal measurements carried out on the same individuals over time would be required to obtain a more accurate rate of telomere erosion.
The presence of significant telomere loss in schizophrenia implies an abnormal aging component in this disorder. Although the cause is unknown, rapid telomere loss can be caused by stress, 2 oxidative damage 5 and DNA instability, 1, 5 mechanisms that have been implicated in schizophrenia pathology. 6, 7 These findings therefore suggest new directions of research that may illuminate the neuropathology of this enigmatic disorder.
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This work was supported by the National Institutes of Health (R01 MH070898 to BP; R01 NS047209 to H-TK; R21 MH071720 to LED; R01 MH044292 to Jurg Ott), the Stanley Research Medical Foundation (BP) and NARSAD. Chronic antidepressant treatment has been shown to increase adult hippocampal neurogenesis. 1 In recent years, it has been widely suggested that the clinical effects of antidepressants may be mediated through an increase in adult hippocampal neurogenesis. 2 This hypothesis is attractive because the delay between stimulating cell proliferation and the production of mature neurons might explain the delayed onset of the clinical effects of antidepressant drugs. In support of this hypothesis, it has been shown that hippocampal neurogenesis is required for the behavioral effects of chronic antidepressants in mice. 2 However, a recent report has cast doubt on these findings. 3 Given the potential importance of this hypothesis, it is necessary to replicate these studies. Here, we use three well-established, behavioral tests of antidepressant action (novelty-suppressed feeding (NSF), open field test and marble burying) and three markers of neurogenesis (bromodeoxyuridine (BrdU), Ki-67 and doublecortin (DCX)) to re-evaluate this hypothesis.
Previous studies have suggested that BALB/cJ mice are especially sensitive to the behavioral effects of fluoxetine treatment. 4 First, we administered fluoxetine to BALB/cJ mice for 14 days (10 mg per kg per day, delivered by Alzet osmotic pump subcutaneously; n = 6 per group). BrdU, a thymidine analog, was injected 150 mg per kg intraperitoneally, 24 h prior to killing. We detected no increase in hippocampal cell proliferation in the dentate gyrus by either of the two markers used (Ki-67: P = 0.59, t = 0.55; BrdU: P = 0.25, t = 1.22).
In a second experiment, we investigated the effects of 30 days of chronic fluoxetine or vehicle treatment in 9-week-old male BALB/cJ mice (n = 11 per group, 10 mg per kg per day delivered by osmotic minipump implanted on day 1; fluoxetine was dissolved in 50% propylene glycol). All mice were injected with BrdU (150 mg per kg) on day 13. Behavior was evaluated on three behavioral tests previously shown to be sensitive to antidepressant treatments (days 26-28). First, NSF was assessed. Mice are more inclined to eat in a novel, potentially dangerous environment following chronic, but not acute, antidepressant treatment. 2, 5 Mice were food deprived for 24 h and then placed in a novel rodent cage (30 Â 50 cm) that contained mouse predator odor (that is, rat feces and fur) for 6 min. Four regular food pellets were placed in the corner of the cage. The total time that the mice spent eating was recorded. Second, mice were put in a brightly lit, white circular open field arena (60 cm diameter). This was arbitrarily divided into an inner (40 cm in diameter) and an outer circular area. Mouse movements were monitored every second for 5 min by an automated tracking system (Videotrack. vNT4.0: Viewpoint). Total distance traveled and time spent in the inner circle were measured. Previous reports show that chronic, but not acute, antidepressant treatment increases the time mice will spend in the center of the open field. 4 Third, marble burying was tested by placing the mice individually into a plastic cage (20 Â 30 cm), with a 5 cm layer of sawdust bedding, which contained 12 glass marbles. Cages were placed on a Threshold system (Med Associates Inc., St. Albans, VT, USA) to monitor digging/burying behavior. After 30 min, the number of marbles that had been buried was counted. Both acute and chronic antidepressant treatments have been shown to reduce marble burying. 6, 7 All mice were killed on day 30. Seven mice in each group were perfused for neurohistology, to assess hippocampal neurogenesis (DCX), cell proliferation (Ki-67) and cell survival (BrdU). The remaining four mice in each group were decapitated and trunk blood was collected for fluoxetine and norfluoxetine analysis.
Results are presented in Table 1 . Fluoxetine-treated mice spent more time engaged in eating behavior in the predator odor cage test (P = 0.04). Fluoxetinetreated mice also tended to spend more time in the center of the open field (P = 0.05). They also buried fewer glass marbles (P = 0.03), and exhibited less digging behavior (P = 0.01). Thus, fluoxetine treatment altered mouse behavior as predicted. However, there was no effect on hippocampal cell proliferation and neurogenesis. There were no group differences in the numbers of labeled cells (DCX, P = 0.41; Ki-67, P = 0.39; BrdU, P = 0.20). The serum levels of fluoxetine and norfluoxetine from the drug-treated mice were within the clinic range. These data show that antidepressant-induced behavioral phenotypes are not necessarily caused by altering hippocampal neurogenesis.
Our data are consistent with the recent report 3 indicating that neurogenesis may not always be required for the behavioral effects of fluoxetine. Our study shows that chronic fluoxetine alters animal behavior without increasing hippocampal neurogenesis in BALB/cJ mice. These results therefore fail to support the currently prevalent hypothesis that stimulation of adult hippocampal neurogenesis underlies the behavioral effects of chronic antidepressants. The adult neurogenesis hypothesis of antidepressant action requires re-evaluation. 
